<DOC>
	<DOCNO>NCT00868491</DOCNO>
	<brief_summary>The purpose study determine efficacy toxicity docetaxel/cisplatin/5-fluorouracil induction chemotherapy ( 4 cycle ) follow concomitant chemoradiation cetuximab weekly cisplatin patient inoperable squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Induction Chemotherapy Followed Chemoradiation With Cetuximab Head Neck Cancer</brief_title>
	<detailed_description>The treatment result radiotherapy inoperable squamous cell carcinoma head neck poor . In proposed single-institution non-randomized , one-arm , open label phase II study , author test efficacy toxicity docetaxel/cisplatin/5-fluorouracil induction chemotherapy ( 4 cycle ) follow concomitant chemoradiation cetuximab weekly cisplatin patient inoperable squamous cell carcinoma head neck . Chemotherapy dose follow : docetaxel 75 mg/m2 I.V . day 1 , cisplatin 75 mg/m2 I.V . day 1 , 5-fluorouracil 750 mg/m2 I.V . continuous infusion day 1-5 repeat every 21 day 4 cycle follow cetuximab 400 mg/m2 I.V . week 13 , cetuximab 250 mg/m2 I.V . week 14-20 , cisplatin 30 mg/m2 I.V . week 14-20 . Three-dimensional conformal radiotherapy planning delivery ( 35x2 Gy/day 7 week { week 14 - 20 } ) use . The planned number patient include 30 anticipated enrolment period 12 month . The primary objective study determine locoregional control 2 year post-therapy , whereas secondary objective determine feasibility ( toxicity profile ) propose regimen , determine complete response rate induction ChT well 14-16 week therapy , completion ChRT determine disease free survival 2 year , overall survival 2 year late toxicity include thyroid function . Given preliminary nature study , stop rule prospectively plan outside observed toxicity , assess grade accord Common Terminology Criteria Adverse Events version 3.0 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Squamous cell carcinoma , histologically proven Tumour site : oral cavity , oropharynx , hypopharynx larynx . Locally and/or regionally inoperable tumor ( UICC TNM stag IVa IVb ) without distant metastasis ( M0stage ) Male female ≥18 year age Expected survival &gt; 6 month Presence least one bidimensionally measurable index lesion Effective contraception male female subject risk conception exists WHO performance status 02 Laboratory parameter : hemoglobin ≥100 g/L leukocyte count &gt; 3.5x109/L , absolute neutrophil count ≥ 1.5x109/L platelet count &gt; 100x109/L total bilirubin &lt; 1.25x upper normal limit transaminase ( ALT , AST ) &lt; 5x upper normal limit creatinine clearance ≥ 55 mls/minute Signed write informed consent Metastatic disease Squamous cell carcinoma nasopharynx nasal cavity paranasal sinuses ChT XRT ineligibility : Unstable cardiac disease medical condition likely compromise safe delivery ChT XRT ; Clinically evident hearing impairment ; Preexisting motor sensory neurotoxicity grade ≥ 2 accord CTCAE v3.0 ; Any kind previous therapy SCCHN ( exclude diagnostic biopsy ) Previous administration EGFR pathwaytargeting therapy Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy part study protocol Participation another clinical trial within 30 day prior study entry Pregnancy breast feed History severe acute pulmonary disease Any investigational agent within past 30 day Other previous malignancy within 5 year , exception history previously adequately treat basal cell carcinoma skin pre invasive carcinoma cervix Known drug abuse / severe alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit subject complete study sign meaningful inform consent Active , uncontrolled infection Other medical condition therapy opinion investigator precludes safe administration plan ChT XRT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>inoperable</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>concomitant radiochemotherapy</keyword>
	<keyword>biological agent</keyword>
	<keyword>efficacy</keyword>
	<keyword>toxicity</keyword>
</DOC>